Featured Article

SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators

In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Download
Press Release
CluePoints Launches Three AI-Led Clinical Data Review Capabilities, Co-Innovated with a Top 10 Pharmaceutical Company
  • Intelligent Query Detection, Medical & Safety Review and Intelligent Medical Coding are now generally available, extending...
Read More
Press Release
CluePoints Appoints Martin Magazzolo as Chief Commercial Officer
  • Wayne, PA – July 27, 2026 – CluePoints, provider of leading statistical and AI-driven software solutions,...
Read More
Press Release
CluePoints and Tufts CSDD Publish Peer-Reviewed Evidence Quantifying the Financial Value of RBQM
  • New research demonstrates RBQM-enabled trials achieve up to 23x ROI and 19% shorter phase durations, providing...
Read More